Blinatumomabe em pacientes pediátricos com leucemia linfoblástica aguda B em primeira recidiva de alto risco: um estudo de custo-efetividade

Beurden-Tan, Chrissy H. Y. van; Ribeiro, Rodrigo Antonini; Seber, Adriana; Lee, Maria a Lucia de Martino; Marçola, Marina; Schuetz, Raphael; Loggetto, Sandra Regina; Maiolino, Angelo.
J. bras. econ. saúde (Impr.) ; 14(1)20220400.
Artículo en Portugués | LILACS, ECOS | ID: biblio-1411772

Documentos relacionados

  1. A systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R/R B-ALL) treatment in children and young adults.
  2. Tisagenlecleucel for relapsed/refractory acute lymphoblastic leukemia in the Irish healthcare setting: cost-effectiveness and value of information analysis.
  3. Spectrum and clinical features of gene mutations in Chinese pediatric acute lymphoblastic leukemia.
  4. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel.
  5. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.
  6. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients.
  7. Potential role of serum vitamin D as a risk factor in pediatric acute lymphoblastic leukemia.
  8. [Infant acute lymphoblastic leukemia: treatment strategies and new insights].
  9. A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia.
  10. Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia.